Sutro Biopharma Receives 'Moderate Buy' Rating from Analysts

Analysts see potential in the biotech company's pipeline of immuno-oncology candidates.

Apr. 12, 2026 at 7:09am

Got story updates? Submit your updates here. ›

An extreme close-up of a complex array of metal gears, cogs, and mechanical components, conveying the intricate and powerful nature of the financial industry's infrastructure and technology.Sutro Biopharma's innovative protein synthesis platform and immuno-oncology pipeline are garnering increased analyst attention, signaling the potential of the company's technology to address unmet needs in cancer and immunology.South San Francisco Today

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have received a consensus 'Moderate Buy' recommendation from the 11 analysts covering the stock, according to MarketBeat Ratings. The average 12-month price target for the stock is $37.38.

Why it matters

Sutro Biopharma is a clinical-stage biotech company focused on developing novel biologic drug candidates in oncology and immunology. Positive analyst sentiment could signal confidence in the company's proprietary protein synthesis platform and pipeline of immuno-oncology therapies.

The details

The analyst ratings break down as follows: two 'sell' ratings, one 'hold' rating, seven 'buy' ratings, and one 'strong buy' rating. Several analysts have recently upgraded their views on Sutro Biopharma, with Deutsche Bank raising its price target to $55 and Citigroup upgrading the stock to 'outperform'.

  • Sutro Biopharma shares opened at $25.86 on Friday, April 12, 2026.
  • The stock has a 52-week range of $5.23 to $27.92.

The players

Sutro Biopharma, Inc.

A clinical-stage biopharmaceutical company focused on developing novel biologic drug candidates in oncology and immunology, leveraging its proprietary cell-free protein synthesis platform.

Deutsche Bank Aktiengesellschaft

A global investment bank that covers Sutro Biopharma and recently raised its price target on the stock.

Citigroup

A multinational investment bank that recently upgraded Sutro Biopharma's stock to an 'outperform' rating.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

Sutro Biopharma's positive analyst sentiment highlights the potential of its innovative protein synthesis platform and immuno-oncology pipeline, as the company aims to develop novel biologic therapies to address unmet needs in cancer and immunology.